Medicaid expansion improves survival and surgical access for pancreatic cancer patients.

• Residents in states with early, on-time, and late Medicaid expansion had 2-year mortality reductions (hazard ratios ranging from 0.91 to 0.94).
• There was a 19% increase in the odds of surgical resection with Medicaid expansion (odds ratio 1.19).

Outcomes improved primarily after three years post-expansion, highlighting the need for equitable access initiatives, especially for lower-income patients.

• Geographic disparities in survival decreased, but income-related disparities persisted.

Transplanting liver patients who respond to atezolizumab-bevacizumab is promising for those with intermediate and advanced hepatocellular carcinoma.

• Recurrence-free survival is 90% and overall survival is 94% at two years post-transplant.
• Acute rejection rates are 25%, but remain manageable; 62.5% had complications within 90 days of transplant.

Surgical teams should consider immunotherapy response when selecting candidates for liver transplantation in advanced HCC.

Dynamic radiomic features from MRI can predict complete response in hepatocellular carcinoma (HCC) post-immune therapy, critical for surgical planning.

• A delta radiomic model achieved an AUC of 0.835 in predicting lesion-level complete response compared to 0.483 for baseline models.
• Combining radiomics with serum AFP response boosted predictive accuracy, yielding AUCs of 0.920 in the test cohort.

Utilizing this model could refine patient selection and improve surgical outcomes for those undergoing hepatectomy.

• Validation across multiple cohorts demonstrates strong generalizability of the findings.